The 'highlight' report from the recent ASH meeting is now available. Slides from the online update meeting can also be accessed here.

Please see here for information about: Post-ASH CML update meeting from the SPIRIT team and CML Professionals' Meeting

We are sometimes asked for information about potential interactions of medications in combination with TKIs. See here for a helpful summary.

A recent analysis of 743 patients in the German CML IV study has confirmed, arguably for the first time, the predictive value of an early PCR measurement in newly treated CML patients.

We thought we would bring to your attention the work of the International Chronic Myeloid Leukemia Foundation.

We are delighted that our 500th patient has now been recruited at Royal Berkshire Hospital!

NICE has today issued an appraisal consultation document (ACD) reviewing the use of dasatinib, nilotinib and high dose imatinib as a second line therapy for patients with CML. This states that dasatinib, nilotinib and high dose imatinib are not recommended for the treatment of CML that is resistant to standard dose imatinib. People who are currently receiving dasatinib, nilotinib or high dose imatinib for imatinib-resistant CML may however continue. A separate technology appraisal looking at imatinib intolerance is ongoing.

Two interesting articles relating to CML have recently been published. The first was a study reporting on the use of imatinib in 'the real world', and the second is a report on the relation between adherence to imatinib and the probabilities of losing a complete cytogenetic response and of imatinib failure.

Thank you to everyone invovled in SPIRIT 2, as we reach the 400 patient mark.

Details for the ESH-ICMLF 13th International Conference on CML Biology and Therapy are now available.

With effect from Tuesday 4 January, the address for the central lab at Hammersmith used for SPIRIT 2 PCR samples will change.

Information following the post-ASH 2010 update meeting (held on 17 December) is available.

New study reported at EHA on the search for a suitable target to potentially develop an antibody therapy in CML.

Nilotinib and dasatinib both show some improvement over imatinib with one year follow up: no long-term survival data yet.

The annual visits are of paramount importance to allow us to accurately measure cytogenetic and molecular treatment response.

We have 2 new eCRF pages for SPIRIT 2.

Dr Kaczmarski - The Hillingdon Hospital NHS Trust

ENESTnd study of up front nilotinib from ASH 2009